A New Merck Reviewed
I will run down, later this weekend, whether New Merck receives any revenue sharing from Australia’s CSL — should these jabs be approved for administration to school-aged boys in that country.
In any event, here is the Australian press report, overnight:
. . . .[All Australian] secondary school boys could soon be offered a free jab to vaccinate them against a sexually transmitted disease that causes cancer.
The makers of the Brisbane-developed cervical cancer vaccine Gardasil have asked the [Australian] Federal Government to extend the highly successful mass immunisation scheme to boys.
The Therapeutic Goods Administration last week approved Gardasil for use on males up to the age of 26.
It is the first step towards a government-funded vaccine rollout for 12 and 13-year-old boys.
The vaccine maker, CSL [as part of a contractual relationship with Merck], has filed an application for the vaccine to be funded for adolescent boys under the National Immunisation Program as a “universal gender neutral program”. . . .
We’ll keep you posted.
[…] This post was mentioned on Twitter by SaneVax, SaneVax. SaneVax said: https://sanevax.org/blog/?p=1078 […]